Medtronic Launches New Pediatric Monitor That Alerts Clinicians To Potential Airway Obstructions During Ventilation

- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. commercial launch of the SonarMed™ airway monitoring system. The first and only device of its kind, the SonarMed airway monitoring system utilizes acoustic technology to check for endotracheal tube (ETT) obstruction and verify position in real-time, giving clinicians vital information required to make more informed, life-saving decisions for their smallest patients.

The Medtronic SonarMed™ airway monitoring system utilizes acoustic technology to check for endotracheal tube (ETT) obstruction and verify position in real-time giving clinicians vital information required to make more informed decisions for their smallest patients.

Globally, 415,000 neonates and infants require invasive mechanical ventilation per year and are intubated for greater than 24 hours. Despite recommendations and reduction efforts, 75,000, or about one in five, of these neonates and infants will experience at least one unplanned extubation (UE). In the NICU, UEs are a significant safety concern for neonates and newborns and are the most common adverse event during mechanical ventilation. 1 These events can lead to increased length of stay and hospital costs. 2 Adoption of the SonarMed airway monitoring system can help reduce the frequency of these events, which in turn can help improve outcomes and reduce healthcare costs.

"The SonarMed airway monitoring device has revolutionized the way we care for our littlest patients. There is no other device in the world that can tell you where the endotracheal tube is located within the airway continuously in real-time, and whether the tube is obstructed or even partially occluded," said Jamie W. Powers , M.D., MBA, neonatologist at Huntington Hospital in Pasadena, California . "At our hospital, this information has led to a drastic reduction in the number of x-rays performed and marked improvement in the effective suctioning of the airway. It also provides the care team and parents the added reassurance that the breathing tube is where it needs to be while repositioning the patient and during kangaroo care. In our institution it has become the new standard of care for all intubated infants."

The SonarMed airway monitoring system is the first and only FDA-cleared airway monitoring system that provides timely notifications and specific measurements that help enable a coordinated response to address potentially critical events such as ETT movement and migration.

"Clinicians face unique challenges in the neonatal intensive care unit (NICU) and pediatric intensive care unit (PICU) daily, ranging from managing oxygenation within extremely tight ranges, to keeping family members informed and comforted. With our innovative technology, this fragile patient group is continuously monitored with a real-time and accurate device that may help improve a clinician's ability to manage the airway and enhance outcomes for our smallest, most vulnerable critical care patients," said Ariel MacTavish , president of the Respiratory Interventions business, which is part of the Medical Surgical Portfolio at Medtronic. "Our goal with introducing the SonarMed technology is to help solve a clinical need to reduce the number of unplanned extubations to help these vulnerable patients start their lives in the healthiest way."

SonarMed, which was acquired by Medtronic in December 2020, specializes in developing solutions that increase patient safety while significantly decreasing healthcare costs.

"With Medtronic's extensive market presence, clinical leadership, and market development expertise, coupled with SonarMed's innovative technology, we are confident that together, we can potentially help save the lives of thousands of infants," said Tom Bumgardner , strategic planning program director, Medtronic Respiratory Interventions, and former SonarMed CEO.

For additional information about the SonarMed airway monitoring system, please visit: medtronic.com/sonarmed .

About SonarMed™ Airway Monitoring System
The SonarMed airway monitoring system includes a bedside monitor and single-use sensor. The SonarMed sensor fits any brand of standard endotracheal tube (ETT) in sizes ranging from neonatal to pediatric populations (2.5 mm–6.0mm ID) and attaches noninvasively to the proximal end of the ETT by replacing the 15-mm connector within the ventilator circuit. The SonarMed monitor incorporates an easy-to-read color screen that can display any change in ETT status.

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

The SonarMed Airway Monitoring System should not be used as the sole basis for diagnosis or therapy and is intended only as an adjunct in patient assessment.

1 The Adverse Impact of Unplanned Extubation in a Cohort of Critically Ill Neonates. 2019. KK Kambestad, A Huack, S Nair, R Chapman, S Chin, L Langga, E Mounger, E Guerrero , NP Iyer. 10.4187/respcare.06721. Respiratory Care.
2 Roddy DJ, Spaeder MC, Pastor W, Stockwell DC, Klugman D. Unplanned Extubations in Children: Impact on Hospital Cost and Length of Stay. Pediatr Crit Care Med . 2015;16(6):572-575. doi:10.1097/PCC.

Contacts:


Kira Jastive

Ryan Weispfenning

Public Relations

Investor Relations

+1-508-452-4238

+1-763-505-4626

The Medtronic SonarMed™ airway monitoring system continuously checks for endotracheal tube obstruction and position for neonates and infants providing immediate, actionable intelligence for clinicians.

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-launches-new-pediatric-monitor-that-alerts-clinicians-to-potential-airway-obstructions-during-ventilation-301287190.html

SOURCE Medtronic plc

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/May2021/10/c0322.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

2023 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company")  announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 21, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
CardieX Limited

Funding Commitment Agreement Update

CARDIEX Limited (ASX:CDX) (CARDIEX, the Company) provides an update on the Funding Commitment Agreement (FCA) with C2 Ventures Pty Limited (C2V, owned by Directors Niall Cairns and Craig Cooper) as announced on 8 November 2023.

Keep reading...Show less

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

  • New pharmacokinetic data demonstrate Virtue ® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within 90 days of balloon delivery
  • AVIM therapy presentation highlighted recent clinical results showing favorable hemodynamic effects and long-term reduction in 24-hour ambulatory systolic blood pressure, as well as the design of the BACKBEAT global pivotal study now enrolling in collaboration with Medtronic, plc (NYSE:MDT)

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced two oral presentations were given at the Cardiovascular Research Technologies ("CRT") 2024 Meeting in Washington, D.C. One presentation featured new preclinical pharmacokinetic ("PK") data on Virtue ® Sirolimus AngioInfusion Balloon ("SAB"), a novel drug-eluting balloon angioplasty system designed to deliver a proprietary, extended-release formulation of sirolimus, SirolimusEFR™ to the vessel wall during balloon angioplasty without any coating on the balloon surface. A second presentation featured recently reported clinical data on atrioventricular interval modulation ("AVIM") therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure. The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×